These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease. Farkas K; Molnár T Immunotherapy; 2018 Feb; 10(2):107-117. PubMed ID: 29124994 [TBL] [Abstract][Full Text] [Related]
4. Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars. Authors' reply. Goncalves J; Magro F; Danese S; Lakatos PL; Ben-Horin S Aliment Pharmacol Ther; 2018 Sep; 48(5):575-576. PubMed ID: 30156326 [No Abstract] [Full Text] [Related]
5. Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease. Lim KJ; Lee SJ; Kim S; Lee SY; Lee MS; Park YA; Choi EJ; Lee EB; Jun HK; Cho JM; Lee S; Kwon KS; Lim BP; Jeon MS; Shin EC; Choi YS; Fudim E; Picard O; Yavzori M; Ben-Horin S; Chang SJ J Crohns Colitis; 2017 May; 11(5):593-602. PubMed ID: 28453766 [TBL] [Abstract][Full Text] [Related]
6. Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients-authors' reply. Komaki Y; Yamada A; Komaki F; Sakuraba A Aliment Pharmacol Ther; 2017 Nov; 46(9):905-906. PubMed ID: 29023885 [No Abstract] [Full Text] [Related]
7. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases. Komaki Y; Yamada A; Komaki F; Micic D; Ido A; Sakuraba A Aliment Pharmacol Ther; 2017 Apr; 45(8):1043-1057. PubMed ID: 28239873 [TBL] [Abstract][Full Text] [Related]
8. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications? Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532 [TBL] [Abstract][Full Text] [Related]
9. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13. Reinisch W; Louis E; Danese S Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():17-26. PubMed ID: 26395531 [TBL] [Abstract][Full Text] [Related]
10. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13. Schreiber S; Panés J; Kwon B; Hong S; Peyrin-Biroulet L Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():5-15. PubMed ID: 26395530 [TBL] [Abstract][Full Text] [Related]